Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study

(2018) E.J.F. Santos et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients

(2017) Kristina Petrulienė et al.   Medicina-Lithuania

Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients

(2017) Kristina Petrulienė et al.   Medicina-Lithuania

Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance

(2017) Sung Woo Lee et al.   Scientific Reports

C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients

(2015) Ibrahim Yılmaz et al.   RENAL FAILURE

Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients

(2015) Scott P. Sibbel et al.   BMC Nephrology

Erythropoietin Resistance Index and the All-Cause Mortality of Chronic Hemodialysis Patients

(2014) Masayuki Okazaki et al.   BLOOD PURIFICATION

The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study

(2014) Zeki Aydin et al.   RENAL FAILURE

Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6

(2013) Richard Rodriguez et al.   INFECTION AND IMMUNITY

Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin

(2013) Theodoros Eleftheriadis et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation

(2013) Y Xu et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation

(2013) A. Icardi et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes

(2013) Andreas Schneider et al.   BMC Nephrology

Ferroportin-mediated iron transport: Expression and regulation

(2012) Diane M. Ward et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR

(2012) J. K. Inrig et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents

(2012) Neelke C. van der Weerd et al.   PLoS One

Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C

(2012) Yasar Caliskan et al.   BMC Nephrology

Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study

(2011) V. Panichi et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia

(2010) Pan-pan Cheng et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Iron, Inflammation, Dialysis Adequacy, Nutritional Status, and Hyperparathyroidism Modify Erythropoietic Response

(2010) A. E. Gaweda et al.   Clinical Journal of the American Society of Nephrology

Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients†

(2010) Karien van der Putten et al.   EUROPEAN JOURNAL OF HEART FAILURE

Is Hepcidin-25 a Clinically Relevant Parameter for the Iron Status in Hemodialysis Patients?

(2010) Lavinia O. Brătescu et al.   JOURNAL OF RENAL NUTRITION

Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients

(2010) Bradley A. Ford et al.   KIDNEY INTERNATIONAL

Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents

(2010) N. Tessitore et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management

(2009) Mehmet Kanbay et al.   BLOOD PURIFICATION

Hepcidin--A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease

(2009) J. Zaritsky et al.   Clinical Journal of the American Society of Nephrology

Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy

(2009) G. Weiss et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin

(2009) D. R. Ashby et al.   HAEMATOLOGICA

Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease

(2009) Damien R. Ashby et al.   KIDNEY INTERNATIONAL

Is hepcidin the star player in iron metabolism in chronic kidney disease?

(2009) Yasuhiro Hamada et al.   KIDNEY INTERNATIONAL

The Role of Hepcidin in Iron Homeostasis and Anemia in Hemodialysis Patients

(2009) Theodoros Eleftheriadis et al.   SEMINARS IN DIALYSIS

Iron Sequestration and Anemia of Inflammation

(2009) Tomas Ganz et al.   SEMINARS IN HEMATOLOGY

Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients

(2008) Elísio Costa et al.   AMERICAN JOURNAL OF NEPHROLOGY

Immunoassay for human serum hepcidin

(2008) T. Ganz et al.   BLOOD

Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality

(2008) Juan M. López-Gómez et al.   KIDNEY INTERNATIONAL